DE60018215D1 - Verbindungen und verfahren zur modulation von estrogen rezeptoren - Google Patents
Verbindungen und verfahren zur modulation von estrogen rezeptorenInfo
- Publication number
- DE60018215D1 DE60018215D1 DE60018215T DE60018215T DE60018215D1 DE 60018215 D1 DE60018215 D1 DE 60018215D1 DE 60018215 T DE60018215 T DE 60018215T DE 60018215 T DE60018215 T DE 60018215T DE 60018215 D1 DE60018215 D1 DE 60018215D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- disclosed
- beta
- methods
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000015694 estrogen receptors Human genes 0.000 title abstract 3
- 108010038795 estrogen receptors Proteins 0.000 title abstract 3
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000033830 Hot Flashes Diseases 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 206010027951 Mood swings Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000024313 Testicular Neoplasms Diseases 0.000 abstract 1
- 206010057644 Testis cancer Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 239000003256 environmental substance Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 208000024963 hair loss Diseases 0.000 abstract 1
- 230000003676 hair loss Effects 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000004240 prostatic hypertrophy Diseases 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 201000003120 testicular cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47577699A | 1999-12-30 | 1999-12-30 | |
| US475776 | 1999-12-30 | ||
| US09/492,939 US6291456B1 (en) | 1998-12-30 | 2000-01-27 | Compounds and methods for modulation of estrogen receptors |
| US492939 | 2000-01-27 | ||
| US611156 | 2000-07-06 | ||
| US09/611,156 US6331562B1 (en) | 1998-12-30 | 2000-07-06 | Compounds and methods for modulation of estrogen receptors |
| PCT/US2000/035671 WO2001049673A2 (en) | 1999-12-30 | 2000-12-29 | Compounds and methods for modulation of estrogen receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60018215D1 true DE60018215D1 (de) | 2005-03-24 |
| DE60018215T2 DE60018215T2 (de) | 2006-02-09 |
Family
ID=27413348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60018215T Expired - Fee Related DE60018215T2 (de) | 1999-12-30 | 2000-12-29 | Verbindungen und verfahren zur modulation von estrogen rezeptoren |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1246814B1 (de) |
| JP (1) | JP2003519219A (de) |
| KR (1) | KR20020075388A (de) |
| CN (1) | CN1281598C (de) |
| AT (1) | ATE289300T1 (de) |
| AU (1) | AU781282B2 (de) |
| CA (1) | CA2396059A1 (de) |
| DE (1) | DE60018215T2 (de) |
| DK (1) | DK1246814T3 (de) |
| ES (1) | ES2238034T3 (de) |
| HK (1) | HK1058521A1 (de) |
| IL (1) | IL150463A0 (de) |
| PT (1) | PT1246814E (de) |
| WO (1) | WO2001049673A2 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5271709A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
| EP1177787A3 (de) * | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung von Katarakt |
| EP1281710A1 (de) * | 2001-08-03 | 2003-02-05 | CHIESI FARMACEUTICI S.p.A. | 2H-1-Benzopyran derivat, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen |
| US7148252B2 (en) * | 2001-10-03 | 2006-12-12 | Signal Pharmaceuticals, Llc | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis |
| EA007382B1 (ru) | 2001-11-19 | 2006-10-27 | Эли Лилли Энд Компани | Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена |
| AU2005202072B2 (en) * | 2001-11-29 | 2008-10-23 | Gtx, Inc. | Prevention and treatment of androgen-deprivation induced conditions |
| SI1460969T1 (sl) * | 2001-11-29 | 2008-10-31 | Gtx Inc | Preprečevanje in zdravljenje s pomanjkanjem androgena inducirane osteoporoze |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| MXPA04010433A (es) * | 2002-04-19 | 2005-08-19 | Signal Pharm Inc | Compuestos benzopiranona, composiciones de estos y los metodos para el tratamiento con estos. |
| US7091235B2 (en) | 2002-10-15 | 2006-08-15 | Signal Pharmaceuticals, Llc | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
| US7674783B2 (en) * | 2002-11-22 | 2010-03-09 | Dimera Inc. | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease |
| EP1618102B1 (de) | 2003-04-21 | 2010-02-10 | Eli Lilly And Company | Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta |
| CA2518819A1 (en) | 2003-04-21 | 2004-11-04 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
| US7098340B2 (en) * | 2003-05-14 | 2006-08-29 | Warner Lambert Company Llc | Benzyl sulfonamide derivatives |
| AU2004274445A1 (en) * | 2003-09-15 | 2005-03-31 | Novartis Ag | Benzopyranone compounds, compositions thereof, and methods of treatment therewith |
| CN101142203A (zh) * | 2005-01-21 | 2008-03-12 | 詹森药业有限公司 | 用作离子通道开放剂的新香豆素衍生物 |
| CA2656067C (en) * | 2006-06-23 | 2014-08-12 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| MX342898B (es) | 2010-05-12 | 2016-10-18 | Radius Health Inc * | Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol. |
| AU2011312490B2 (en) | 2010-09-28 | 2015-06-25 | Radius Pharmaceuticals, Inc. | Selective androgen receptor modulators |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| HUE061499T2 (hu) | 2014-03-28 | 2023-07-28 | Univ Duke | Mellrák kezelése szelektív ösztrogénreceptor-módosítók alkalmazásával |
| CN105801543B (zh) * | 2016-04-18 | 2019-08-02 | 中国药科大学 | 4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
| CN105801544A (zh) * | 2016-04-18 | 2016-07-27 | 中国药科大学 | 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
| AU2017281038B2 (en) | 2016-06-22 | 2021-09-09 | Ellipses Pharma Ltd | AR+ breast cancer treatment methods |
| CN106727637A (zh) * | 2016-12-27 | 2017-05-31 | 郑州郑先医药科技有限公司 | 一种治疗白内障的西药组合物及其用途 |
| CN106492204A (zh) * | 2016-12-27 | 2017-03-15 | 郑州郑先医药科技有限公司 | 一种治疗白内障的药物组合物 |
| CN110191707A (zh) | 2017-01-05 | 2019-08-30 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726202A (en) * | 1996-01-11 | 1998-03-10 | Novo Nordisk A/S | Benign prostatic hypertrophy |
| BR9706967A (pt) * | 1996-01-11 | 1999-05-04 | Novo Nordisk As | Utilização de compostos e processo para tratamento e profilaxia de sintomas relacionados à menopausa |
| US5883118A (en) * | 1996-01-11 | 1999-03-16 | Nova Nordisk A/S | Prostatic carcinoma |
| WO2000039120A2 (en) * | 1998-12-30 | 2000-07-06 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
-
2000
- 2000-12-29 CN CNB008192227A patent/CN1281598C/zh not_active Expired - Fee Related
- 2000-12-29 DK DK00990966T patent/DK1246814T3/da active
- 2000-12-29 CA CA002396059A patent/CA2396059A1/en not_active Abandoned
- 2000-12-29 WO PCT/US2000/035671 patent/WO2001049673A2/en active IP Right Grant
- 2000-12-29 JP JP2001550213A patent/JP2003519219A/ja active Pending
- 2000-12-29 ES ES00990966T patent/ES2238034T3/es not_active Expired - Lifetime
- 2000-12-29 AT AT00990966T patent/ATE289300T1/de not_active IP Right Cessation
- 2000-12-29 AU AU30771/01A patent/AU781282B2/en not_active Ceased
- 2000-12-29 KR KR1020027008569A patent/KR20020075388A/ko active IP Right Grant
- 2000-12-29 PT PT00990966T patent/PT1246814E/pt unknown
- 2000-12-29 DE DE60018215T patent/DE60018215T2/de not_active Expired - Fee Related
- 2000-12-29 EP EP00990966A patent/EP1246814B1/de not_active Expired - Lifetime
- 2000-12-29 IL IL15046300A patent/IL150463A0/xx unknown
-
2004
- 2004-02-20 HK HK04101233A patent/HK1058521A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003519219A (ja) | 2003-06-17 |
| AU781282B2 (en) | 2005-05-12 |
| CN1437591A (zh) | 2003-08-20 |
| ATE289300T1 (de) | 2005-03-15 |
| WO2001049673A3 (en) | 2001-12-06 |
| DK1246814T3 (da) | 2005-05-30 |
| EP1246814B1 (de) | 2005-02-16 |
| WO2001049673A2 (en) | 2001-07-12 |
| ES2238034T3 (es) | 2005-08-16 |
| CN1281598C (zh) | 2006-10-25 |
| PT1246814E (pt) | 2005-07-29 |
| KR20020075388A (ko) | 2002-10-04 |
| AU3077101A (en) | 2001-07-16 |
| IL150463A0 (en) | 2002-12-01 |
| CA2396059A1 (en) | 2001-07-12 |
| HK1058521A1 (en) | 2004-05-21 |
| EP1246814A2 (de) | 2002-10-09 |
| DE60018215T2 (de) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60018215D1 (de) | Verbindungen und verfahren zur modulation von estrogen rezeptoren | |
| ATE248157T1 (de) | Verbindungen und verfahren zur modulation von estrogen rezeptoren | |
| WO2000055137A8 (en) | Compounds and methods for modulation of estrogen receptors | |
| MY115784A (en) | Estrogen agonists/antagonists | |
| CY1111195T1 (el) | Ρυθμιστες υποδοχεων οιστρογονου | |
| CR6478A (es) | Moduladores del receptor glucocorticoide | |
| MY112949A (en) | Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia | |
| DE3587262D1 (de) | Verfahren zum produzieren von knochenzement zur fixierung von prothesen und vorrichtung zur durchfuehrung dieses verfahrens. | |
| BR0010215A (pt) | Derivados de indolina como antagonistas de progesterona | |
| EA200300474A1 (ru) | Модуляторы рецепторов эстрогена | |
| AU2002367060A8 (en) | Heterocyclic modulators of nuclear receptors | |
| ATE309760T1 (de) | Vorrichtung zur bildung von löchern und einführhülsen in einer in einem dentalbefestigungsteil enthaltenen einheit | |
| ATE250077T1 (de) | Steroid sulfataseinhibitoren, verfahren zu ihrer herstellung und verwendung | |
| DE59911879D1 (de) | Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie | |
| ATE254122T1 (de) | Indolderivate als 5-ht1b und 5-ht1d agonisten | |
| NO20020260D0 (no) | 11<beta>-aryl-17,17-spirotiolansubstituerte steroider | |
| Meyers | The role of hormone receptors in estrogen activity is questionable | |
| Charnock-Jones et al. | Vascular endothelial growth factor and corpus luteum angiogenesis | |
| ATE342055T1 (de) | Verwendung von steroidalen estrogenrezeptorantagonisten zur männlichen fertilitätskontrolle | |
| ATE370226T1 (de) | Maus brustkrebs zelllinien die estrogen und progesteron rezeptoren exprimieren | |
| MY137604A (en) | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | |
| Boyde | Stereographic visual aids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: SIGNAL PHARMACEUTICALS LLC, SAN DIEGO, CALIF., US |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |